Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2015-11, Vol.50 (11), p.1486-1486
Hauptverfasser:	Minoia, C, Pisapia, G, Palazzo, G, Ingrosso, C, Buonanno, M, Spinosa, C, Prudenzano, A, Pricolo, G, Mazza, P
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308 692/699/67/1990/804 Aged Angiogenesis Inhibitors - administration & dosage Angiogenesis Inhibitors - therapeutic use Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autografts Bone marrow Bortezomib Bortezomib - administration & dosage Bortezomib - therapeutic use Cell Biology Cyclophosphamide - pharmacology Drug therapy Elderly patients Female Filgrastim Granulocyte Colony-Stimulating Factor - pharmacology Hematology Hematopoietic Stem Cell Mobilization Hematopoietic Stem Cell Transplantation Hematopoietic stem cells Humans Interferon-alpha - administration & dosage Internal Medicine letter-to-the-editor Male Medicine Medicine & Public Health Multiple myeloma Multiple Myeloma - drug therapy Multiple Myeloma - therapy Patient outcomes Physiological aspects Polyethylene Glycols Proteasome Inhibitors - administration & dosage Proteasome Inhibitors - therapeutic use Public Health Recombinant Proteins - pharmacology Remission Induction Retrospective Studies Stem cell transplantation Stem Cells Thalidomide - administration & dosage Thalidomide - therapeutic use Transplantation Transplantation Conditioning Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:
ISSN:	0268-3369 1476-5365
DOI:	10.1038/bmt.2015.185